Tabimorelin Molecular Structure & Chemistry

Tabimorelin, a prominent orally active growth-hormone secretagogue (GHS), is extensively studied in endocrine and cellular research for its unique molecular structure and intricate chemical properties. Its mechanism involves specific interactions with the growth hormone secretagogue receptor (GHS-R), making it a valuable tool for investigating hormonal regulation and associated cellular pathways.

Research into Tabimorelin’s molecular intricacies contributes significantly to the understanding of peptidomimetic pharmacology and GHS-R agonism. The compound has been the subject of numerous scientific publications indexed in PubMed and has been investigated in several registered studies on ClinicalTrials.gov, highlighting its persistent relevance in elucidating fundamental biological processes relevant to cellular aging research and beyond, strictly within an investigative framework.

Tabimorelin: A Peptidomimetic Growth-Hormone Secretagogue

Tabimorelin represents a significant advancement in the field of endocrine research, particularly as an orally active growth-hormone secretagogue (GHS). Belonging to a distinct class of compounds that stimulate the release of growth hormone (GH) from the anterior pituitary gland, Tabimorelin differentiates itself through its peptidomimetic structure. Unlike endogenous growth hormone-releasing hormone (GHRH) or traditional peptide-based GHS, which often suffer from poor oral bioavailability and rapid enzymatic degradation, peptidomimetics are engineered to retain the pharmacological activity of their peptide counterparts while possessing enhanced drug-like properties. This structural design enables Tabimorelin to be a valuable tool for investigating GH axis regulation in various research models, providing insights into metabolic processes, body composition, and endocrine functions without the limitations associated with injectable peptide administration. The study of such compounds is critical for understanding fundamental biological mechanisms related to growth and metabolism. For a broader understanding of this class of compounds, researchers may refer to our introduction to research peptides.

The term “peptidomimetic” implies that Tabimorelin structurally mimics the essential features of a peptide ligand, allowing it to bind to and activate specific receptors, yet it is not itself a true peptide. This is typically achieved by incorporating non-peptidic backbones, unnatural amino acids, or cyclic structures that confer increased stability against proteolytic enzymes and improved membrane permeability. In the case of Tabimorelin, its specific chemical architecture has been optimized to interact effectively with the growth hormone secretagogue receptor type 1a (GHSR-1a), which is the primary target for ghrelin and other GHS. This strategic design makes Tabimorelin a potent and selective agonist, driving the release of GH through a distinct signaling pathway compared to GHRH, which acts via its own receptor. The ability to modulate the GH axis through an orally active agent has profoundly impacted the feasibility and scope of endocrine research.

Research into Tabimorelin’s mechanism and effects has been extensive, as evidenced by numerous publications indexed in PubMed and several registered studies on ClinicalTrials.gov. These investigations span a range of topics, from its basic pharmacological profile to its potential applications in various preclinical models exploring conditions related to GH deficiency, muscle wasting, and metabolic dysregulation. The availability of such a compound allows researchers to delve deeper into the complex interplay between the GH axis, metabolism, and aging, offering a precise tool for perturbing specific physiological systems. Understanding the detailed molecular structure and chemical properties of Tabimorelin is therefore paramount for interpreting experimental outcomes accurately and for designing future research endeavors aimed at elucidating novel therapeutic strategies.

Detailed Chemical Synthesis Pathways and Precursors

The successful synthesis of Tabimorelin, a complex peptidomimetic, relies on sophisticated multi-step chemical procedures designed to ensure high purity and yield, critical for rigorous research applications. Unlike simple peptides that can often be assembled linearly via solid-phase peptide synthesis (SPPS), the non-peptidic backbone and specific stereochemistry of Tabimorelin necessitate a combination of solution-phase and sometimes specialized solid-phase techniques. A typical synthesis strategy involves assembling key structural fragments separately and then coupling them in a highly controlled manner. This modular approach allows for the optimization of each sub-synthesis step, addressing challenges such as stereoselectivity, regioselectivity, and the handling of sensitive functional groups. Protecting group strategies are meticulously planned to prevent undesired side reactions and facilitate selective deprotection at appropriate stages.

Key Precursors and Intermediate Synthesis

The synthesis of Tabimorelin typically commences with readily available starting materials, which are then elaborated into more complex chiral building blocks. These precursors often include specific substituted heterocyclic compounds, amino acids (natural or unnatural), and various amines or carboxylic acids. For example, specific pyrazole or pyridine derivatives might form the core heterocyclic scaffold, while appropriately protected diamines or dicarboxylic acids contribute to the linker regions. Each intermediate must undergo stringent purification and characterization to ensure the integrity of the growing molecule. Chromatographic techniques, such as column chromatography and recrystallization, are routinely employed to isolate and purify intermediates, while analytical methods like nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) confirm their identity and purity before proceeding to the next step.

Challenges in Peptidomimetic Synthesis

The synthesis of peptidomimetics like Tabimorelin presents several inherent challenges that demand precise execution and advanced chemical expertise:

Chirality Control: Many peptidomimetics possess multiple chiral centers. Maintaining or establishing the correct stereochemistry at each center is paramount, as different stereoisomers can exhibit drastically different biological activities or even be inactive. Chiral auxiliaries, asymmetric catalysis, or diastereoselective reactions are often critical in these steps.
Regioselectivity: When multiple reactive sites are present on a molecule, ensuring that reactions occur at the desired position (regioselectivity) is crucial. This often involves careful choice of reagents, reaction conditions, and temporary protecting groups to direct reactivity.
Protecting Group Strategies: Complex molecules with multiple functional groups require sophisticated protecting group schemes. The choice of protecting groups must consider their compatibility with various reaction conditions and their selective removal without affecting other parts of the molecule.
Coupling Efficiency: Forming amide bonds, particularly between sterically hindered fragments or those with non-standard amino acid structures, requires efficient coupling reagents and optimized reaction conditions to maximize yield and minimize epimerization.

The final steps typically involve the global deprotection of the assembled peptidomimetic, followed by extensive purification to obtain the research-grade Tabimorelin. High-performance liquid chromatography (HPLC), often preparative HPLC, is indispensable for achieving the high purity levels demanded for biological research, removing residual reagents, side products, and truncated sequences. The rigorous nature of these synthetic pathways underscores the intricate chemistry involved in producing high-quality research compounds.

Stereochemistry and Conformational Analysis of Tabimorelin

The biological activity of Tabimorelin is intimately linked to its precise three-dimensional structure, making the study of its stereochemistry and conformational preferences essential for understanding its mechanism of action and optimizing its properties. Stereochemistry refers to the spatial arrangement of atoms within the molecule, particularly concerning chiral centers, where a carbon atom is bonded to four different groups. Tabimorelin, as a complex organic molecule, possesses several chiral centers, and the absolute configuration at each of these centers dictates the molecule’s overall shape and its ability to interact specifically with the GHSR-1a receptor. Even a subtle change in stereochemistry, such as the inversion of configuration at a single chiral center, can lead to a drastic reduction or complete loss of biological activity, underscoring the exquisite selectivity of receptor-ligand interactions.

Techniques for Stereochemical Determination

The determination of the absolute and relative stereochemistry of Tabimorelin and its intermediates relies on a combination of advanced analytical techniques:

Nuclear Magnetic Resonance (NMR) Spectroscopy: High-field NMR, including 1D (¹H, ¹³C) and 2D (COSY, NOESY, HSQC, HMBC) experiments, provides detailed information about the connectivity and spatial relationships between atoms. NOESY (Nuclear Overhauser Effect Spectroscopy) experiments are particularly valuable for determining relative stereochemistry by identifying protons that are in close proximity in space.
X-ray Crystallography: If Tabimorelin can be crystallized, X-ray diffraction can provide an unambiguous determination of its absolute three-dimensional structure, including all bond lengths, bond angles, and torsion angles, as well as the absolute configuration of chiral centers. This technique offers the most direct evidence of molecular structure.
Chiral Chromatography: High-performance liquid chromatography (HPLC) utilizing chiral stationary phases can separate enantiomers and diastereomers, allowing for the assessment of enantiomeric purity and the identification of specific stereoisomers. This is crucial for quality control in research applications.
Optical Rotation: Measurement of optical rotation can indicate the presence of chiral compounds and, when combined with other data, help confirm the absolute configuration if reference compounds are available.

Conformational Flexibility and Receptor Binding

Beyond static stereochemistry, the dynamic conformational analysis of Tabimorelin is crucial. Molecules are not rigid entities but possess conformational flexibility due to rotation around single bonds. This flexibility allows a molecule to adopt various three-dimensional shapes, and often, only a specific “bioactive conformation” is capable of optimal binding and activation of its target receptor. Computational chemistry and molecular modeling techniques, such as molecular dynamics simulations and conformational searching algorithms, are indispensable tools for exploring the conformational landscape of Tabimorelin. These simulations can predict low-energy conformations in solution and at the receptor binding site, providing insights into how the molecule might adapt to fit the receptor’s pocket. The balance between conformational flexibility (necessary for initial binding) and rigidity (necessary for precise interaction and activation) is a critical design consideration for peptidomimetics, influencing factors such as binding affinity, receptor selectivity, and overall biological efficacy.

Understanding the intricate stereochemical details and conformational preferences of Tabimorelin is not merely an academic exercise; it directly informs structure-activity relationship (SAR) studies, guides the rational design of new analogues, and assists in the interpretation of complex biological data. For example, if a specific conformation is identified as crucial for receptor binding, future modifications can be strategically introduced to stabilize that preferred conformation, potentially leading to compounds with improved potency or altered pharmacokinetic profiles in research models.

Structure-Activity Relationships (SAR) for GH Secretagogue Efficacy

The meticulous investigation of Structure-Activity Relationships (SAR) is fundamental to understanding how Tabimorelin exerts its growth hormone secretagogue (GHS) effects and for the rational design of novel compounds with enhanced properties. SAR studies systematically explore how modifications to specific parts of the Tabimorelin molecule impact its binding affinity to the GHSR-1a receptor, its intrinsic efficacy (ability to activate the receptor), and its overall pharmacological profile. This involves synthesizing a series of analogues where different functional groups, substituents, or backbone elements are altered, and then evaluating their biological activity in appropriate *in vitro* and *in vivo* research models. The goal is to delineate the pharmacophore – the essential ensemble of steric and electronic features required for optimal interaction with the receptor – and to identify regions of the molecule that can be modified without compromising, or even enhancing, activity.

Critical Structural Motifs for GHSR-1a Binding and Activation

Through extensive SAR studies on Tabimorelin and related GHS peptidomimetics, several key structural motifs have been identified as crucial for GHSR-1a binding and activation:

Hydrophobic Core: A central hydrophobic region is often essential for establishing favorable van der Waals interactions within the lipophilic binding pocket of the GHSR-1a. Modifications to the size, shape, and lipophilicity of this core can significantly influence binding affinity.
Basic Nitrogen Atom: Many GHS, including Tabimorelin, feature a basic nitrogen atom (e.g., in a heterocyclic ring or an amine functionality) that is thought to interact with an acidic residue within the receptor’s transmembrane domain. This electrostatic interaction is often critical for high-affinity binding and receptor activation.
Hydrogen Bonding Donors/Acceptors: Specific hydrogen bond donor and acceptor groups strategically positioned on the molecule are vital for forming precise interactions with complementary residues in the GHSR-1a. These interactions contribute to binding specificity and can influence the conformational changes required for receptor activation.
Aromatic Rings: Aromatic or heteroaromatic rings often play a role in establishing pi-stacking interactions with aromatic residues in the receptor, further stabilizing the ligand-receptor complex and contributing to specificity.

The precise arrangement and spatial orientation of these motifs, as governed by the molecule’s stereochemistry and conformational preferences, are paramount. Even seemingly minor changes, such as altering the position of a methyl group or swapping an amide bond for an ester, can disrupt these critical interactions and abolish activity.

Impact of Structural Modifications on Efficacy and Selectivity

Systematic modifications around the Tabimorelin scaffold allow researchers to fine-tune its properties. For instance, altering the substituents on the aromatic rings can modulate lipophilicity, which in turn affects membrane permeability and metabolic stability in research models. Changes to the linker regions connecting different structural domains can impact conformational flexibility, potentially favoring a more active conformation or improving receptor residence time. Moreover, SAR studies can reveal insights into selectivity; by introducing specific modifications, researchers might develop analogues that preferentially activate GHSR-1a over other closely related G protein-coupled receptors (GPCRs), minimizing potential off-target effects in complex biological systems. This iterative process of synthesis, biological evaluation, and structural analysis forms the backbone of rational drug design in discovering and optimizing research compounds like Tabimorelin, moving beyond simple empiricism to a more predictive understanding of ligand-receptor interactions.

Pharmacokinetic Principles and Metabolic Stability in Research Models

For any research compound, especially orally active peptidomimetics like Tabimorelin, understanding its pharmacokinetic (PK) profile and metabolic stability is paramount for interpreting *in vivo* research findings and designing effective experimental protocols. Pharmacokinetics describes what the body does to the compound – encompassing absorption, distribution, metabolism, and excretion (ADME). Metabolic stability, a critical component of ADME, refers to the compound’s resistance to enzymatic degradation within biological systems. The optimization of these parameters is crucial for ensuring that a sufficient concentration of the active compound reaches its target receptor and remains available for the duration required to elicit a biological effect in various research models.

Absorption and Oral Bioavailability

A key advantage of Tabimorelin over peptide-based GH secretagogues is its oral activity, which implies favorable absorption characteristics. Oral bioavailability is influenced by several factors, including permeability across gastrointestinal membranes and resistance to degradation by enzymes in the gut and liver (first-pass metabolism). Unlike larger, hydrophilic peptides, Tabimorelin’s peptidomimetic structure often confers enhanced lipophilicity and proteolytic stability, allowing it to traverse biological barriers more effectively. Research models often utilize *in vitro* Caco-2 cell permeability assays and *in vivo* oral gavage studies in rodents or non-human primates to quantify absorption rates and assess overall oral bioavailability. Low oral bioavailability can necessitate higher dosing or alternative administration routes in research, complicating experimental design and interpretation.

Distribution and Metabolism

Once absorbed, Tabimorelin distributes throughout the body’s tissues and fluids. Its distribution pattern is influenced by factors such as plasma protein binding, tissue permeability, and affinity for specific transporters. High plasma protein binding, for instance, can limit the free fraction of the compound available to interact with its target receptor. Metabolism, primarily occurring in the liver but also in other tissues, involves enzymatic modification of the compound. For peptidomimetics, common metabolic pathways include:

Oxidation: Catalyzed predominantly by cytochrome P450 (CYP) enzymes, particularly prevalent for compounds containing aromatic rings or alkyl chains.
Hydrolysis: While Tabimorelin is designed for proteolytic stability, specific ester or amide bonds might still be susceptible to hydrolysis by esterases or less specific amidases.
Conjugation: Attachment of polar molecules (e.g., glucuronidation, sulfation) to facilitate excretion.

Metabolic stability is often assessed *in vitro* using liver microsomes, hepatocytes, or S9 fractions, which provide information on intrinsic clearance. Compounds with high *in vitro* metabolic stability tend to have longer half-lives *in vivo*, allowing for more sustained receptor engagement in research models. Identification of major metabolites through techniques like LC-MS/MS is also important to understand potential secondary activities or toxicological profiles in research contexts.

Excretion and Half-Life

The excretion of Tabimorelin and its metabolites occurs primarily via renal (kidney) or biliary (liver and bile) routes. The rate of excretion, combined with metabolism, dictates the compound’s half-life – the time it takes for the concentration of the compound in plasma to reduce by half. A longer half-life generally translates to less frequent dosing requirements in *in vivo* research, which can be advantageous for chronic studies. Researchers use plasma concentration-time profiles from *in vivo* studies to calculate PK parameters such as half-life (t_1/2), area under the curve (AUC), maximum concentration (C_max), and time to C_max (T_max). Understanding these pharmacokinetic principles allows researchers to accurately dose Tabimorelin in various experimental models, optimize the timing of interventions, and confidently correlate observed biological effects with systemic exposure to the research compound.

Receptor Binding Kinetics and Signaling Mechanisms of Tabimorelin

The physiological effects of Tabimorelin as a growth-hormone secretagogue are initiated by its precise interaction with the growth hormone secretagogue receptor type 1a (GHSR-1a). This receptor, a member of the G protein-coupled receptor (GPCR) family, is predominantly expressed in the anterior pituitary gland, as well as in other central and peripheral tissues, indicating its broad role in endocrine and metabolic regulation. Understanding the kinetics of Tabimorelin’s binding to GHSR-1a and the subsequent intracellular signaling cascade is crucial for elucidating its mechanism of action and for predicting its pharmacological profile in diverse research models. Researchers can find more details on its action here.

Binding Affinity and Receptor Occupancy

Receptor binding kinetics describe how Tabimorelin interacts with GHSR-1a. Key parameters include binding affinity (K_d or K_i), which quantifies the strength of the ligand-receptor interaction, and kinetic rates such as association (k_on) and dissociation (k_off). Tabimorelin is characterized by a high affinity for GHSR-1a, indicating that it can bind effectively even at low concentrations, displacing endogenous ligands if present. High-affinity binding is a prerequisite for potent biological activity. Receptor occupancy, the fraction of receptors bound by the ligand, is directly related to concentration and affinity, influencing the magnitude of the downstream signaling response. Techniques such as radioligand binding assays, fluorescence polarization, or surface plasmon resonance (SPR) are commonly employed *in vitro* to characterize these binding parameters, providing quantitative data on Tabimorelin’s interaction with the GHSR-1a.

G Protein-Coupled Receptor (GPCR) Signaling Cascade

Upon binding to GHSR-1a, Tabimorelin induces a conformational change in the receptor, which then couples to and activates specific intracellular G proteins. GHSR-1a primarily couples to G_q/11 proteins, leading to the activation of the phospholipase C (PLC) pathway. This cascade involves a series of intracellular events:

G_q/11 Protein Activation: Binding of Tabimorelin causes the G_q/11 protein to exchange GDP for GTP, leading to its dissociation into active α-G_q/11 and βγ subunits.
Phospholipase C (PLC) Activation: The activated α-G_q/11 subunit stimulates PLC, an enzyme that hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP₂), a membrane phospholipid.
Formation of IP₃ and DAG: Hydrolysis of PIP₂ generates two important second messengers: inositol 1,4,5-trisphosphate (IP₃) and diacylglycerol (DAG).
Intracellular Calcium Release: IP₃ binds to IP₃ receptors on the endoplasmic reticulum, triggering the release of intracellular calcium (Ca²⁺) stores into the cytoplasm. This increase in intracellular Ca²⁺ is a hallmark of GHSR-1a activation.
Protein Kinase C (PKC) Activation: DAG, in conjunction with elevated Ca²⁺, activates protein kinase C (PKC), which then phosphorylates various downstream target proteins, mediating further cellular responses.

The sustained elevation of intracellular Ca²⁺ and subsequent activation of PKC are critical events that ultimately lead to the exocytosis of growth hormone vesicles from somatotrophs in the anterior pituitary. This detailed understanding of Tabimorelin’s signaling pathway is crucial for researchers studying its impact on GH secretion and its broader physiological roles in various research models.

Beyond the primary G_q/11 pathway, GHSR-1a has also been shown to couple to other signaling pathways, including those involving G_i/o proteins, leading to inhibition of adenylyl cyclase

Frequently Asked Questions

What is the chemical classification of Tabimorelin?

Tabimorelin is classified as a peptidomimetic, meaning it mimics the biological activity of a peptide (ghrelin, in this case) but possesses a non-peptidic structure that often confers advantages such as oral bioavailability and increased metabolic stability in research models.

How does Tabimorelin’s molecular structure relate to its GH secretagogue activity?

The specific arrangement of functional groups and stereochemical centers within Tabimorelin’s molecular structure is critical for its high affinity and selectivity for the growth hormone secretagogue receptor (GHS-R1a), enabling it to activate the receptor and elicit a growth hormone secretagogue effect in research contexts.

What are common analytical methods used to characterize Tabimorelin in a laboratory setting?

Researchers commonly employ a suite of analytical techniques for Tabimorelin characterization, including High-Performance Liquid Chromatography (HPLC) for purity and quantification, Mass Spectrometry (MS) for molecular weight and structural elucidation, Nuclear Magnetic Resonance (NMR) spectroscopy for detailed structural confirmation, and X-ray crystallography for definitive three-dimensional structure determination.

Is Tabimorelin considered a traditional peptide?

No, Tabimorelin is not a traditional peptide composed solely of alpha-amino acids linked by peptide bonds. Instead, it is a synthetic, non-peptidic small molecule designed to mimic the actions of the endogenous peptide ghrelin, making it a peptidomimetic.

What distinguishes Tabimorelin from other GH secretagogues structurally?

Tabimorelin possesses a unique chemical scaffold that differentiates it from other growth hormone secretagogues. While many GHS compounds share common pharmacophoric elements for GHS-R1a binding, Tabimorelin’s specific ring systems and side chain attachments contribute to its distinct receptor binding profile and pharmacokinetic properties observed in research studies.

Has Tabimorelin’s metabolism been studied at a molecular level in research models?

Yes, research has explored the metabolic pathways of Tabimorelin in various *in vitro* and *in vivo* animal models. These studies aim to identify potential metabolites, elucidate enzymes involved in its biotransformation, and understand how its molecular structure influences its metabolic fate and half-life in a biological system.

What is the significance of Tabimorelin’s oral activity from a research perspective?

From a research perspective, Tabimorelin’s oral activity is significant because it allows for less invasive administration in animal models compared to injectable compounds, facilitating long-term studies and investigations into chronic effects or sustained receptor activation patterns without the logistical complexities of continuous infusion.

Where can researchers find comprehensive information on Tabimorelin’s studies and molecular data?

Researchers can access comprehensive information on Tabimorelin through scientific literature databases such as PubMed, which indexes numerous peer-reviewed publications detailing its molecular structure, synthesis, mechanisms, and findings from *in vitro* and *in vivo* animal studies. Additionally, information on clinical research investigations can be found on platforms like ClinicalTrials.gov, which lists several registered studies.

Scientific References

All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.

Tabimorelin Molecular Structure & Chemistry — Research Reference